Zinc Coordination Is Required for and Regulates Transcription Activation by Epstein-Barr Nuclear Antigen 1 by Aras, Siddhesh et al.
Zinc Coordination Is Required for and Regulates
Transcription Activation by Epstein-Barr Nuclear Antigen 1
Siddhesh Aras
1,2, Gyanendra Singh
2, Kenneth Johnston
1, Timothy Foster
1,3, Ashok Aiyar
1,2*
1Department of Microbiology, Immunology & Parasitology, LSU Health Sciences Center, New Orleans, Louisiana, United States of America, 2Stanley S. Scott Cancer
Center, LSU Health Sciences Center, New Orleans, Louisiana, United States of America, 3The Gene Therapy Program, LSU Health Sciences Center, New Orleans, Louisiana,
United States of America
Abstract
Epstein-Barr Nuclear Antigen 1 (EBNA1)is essential for Epstein-Barr virus to immortalize naı ¨ve B-cells. Upon binding a cluster of
20 cognate binding-sites termed the family of repeats, EBNA1 transactivates promoters for EBV genes that are required for
immortalization. A small domain, termed UR1, that is 25 amino-acids in length, has been identified previously as essential for
EBNA1 to activate transcription. In this study, we have elucidated how UR1 contributes to EBNA1’s ability to transactivate. We
show that zinc is necessary for EBNA1 to activate transcription, and that UR1 coordinates zinc through a pair of essential
cysteines contained within it. UR1 dimerizes upon coordinating zinc, indicating that EBNA1 contains a second dimerization
interface in its amino-terminus. There is a strong correlation between UR1-mediated dimerization and EBNA1’s ability to
transactivate cooperatively. Point mutants of EBNA1 that disrupt zinc coordination also prevent self-association, and do not
activate transcription cooperatively. Further, we demonstrate that UR1 acts as a molecular sensor that regulates the ability of
EBNA1 to activate transcription in response to changes in redox and oxygen partial pressure (pO2). Mild oxidative stress
mimicking such environmental changes decreases EBNA1-dependent transcription in a lymphoblastoid cell-line. Coincident
with a reduction in EBNA1-dependent transcription, reductions are observed in EBNA2 and LMP1 protein levels. Although
these changes do not affect LCL survival, treated cells accumulate in G0/G1. These findings are discussed in the context of EBV
latency in body compartments that differ strikingly in their pO2 and redox potential.
Citation: Aras S, Singh G, Johnston K, Foster T, Aiyar A (2009) Zinc Coordination Is Required for and Regulates Transcription Activation by Epstein-Barr Nuclear
Antigen 1. PLoS Pathog 5(6): e1000469. doi:10.1371/journal.ppat.1000469
Editor: Samuel H. Speck, Emory University, United States of America
Received December 30, 2008; Accepted May 12, 2009; Published June 12, 2009
Copyright:  2009 Aras et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by NIH RO1 CA112564, and funds from the Stanley S. Scott Cancer Center at LSUHSC, and the Gene Therapy
Consortium at LSUHSC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: aaiyar@lsuhsc.edu
Introduction
Epstein-Barr nuclear antigen 1 (EBNA1) has two functions that
are necessary for Epstein-Barr virus (EBV) to immortalize naı ¨ve
human B-cells. EBNA1 is essential for the replication and
partitioning of EBV genomes in latently-infected cells [1], and
activates the transcription of EBV genes that are essential for
immortalization [2]. In earlier studies, the ability of EBNA1 to
activate transcription was closely correlated to its ability to support
EBV genome replication and partitioning during latency. Both
activities require EBNA1 to bind a series of cognate binding sites
termed the family of repeats (FR), and alterations in repeat
number caused proportional variations in both functions [3].
There have been recent advances in understanding how
EBNA1 activates the transcription from EBV promoters. It is
known that occupancy of specific sequences by the chromatin
boundary factor, CTCF, regulates EBNA1’s ability to activate
specific viral promoters during latency [4]. Additionally, studies
have also distinguished the ability of EBNA1 to activate
transcription from its ability to support the replication and
partitioning of EBV genomes. The amino-terminal half of EBNA1
contains two positively-charged regions with alternating glycines
and arginines that can bind AT-rich DNA in a manner similar to
AT-hook proteins [5]. Indeed, the amino-terminal 450 amino-
acids of EBNA1 can be replaced with a cellular AT-hook protein,
HMGA1a, and the resulting chimera HMGA1a-DBD, supports
replication and partitioning of oriP-plasmids and EBV genomes in
transformed cell-lines [2,6,7]. Considering the role of HMGA1a in
the formation of transcription enhanceosomes [8,9], HMGA1a-
DBD is surprisingly deficient in the ability to activate transcription
from EBV promoters [2,6]. These studies indicate that either AT-
hook function is insufficient for transcription activation, or that it is
irrelevant to the ability of EBNA1 to activate transcription.
Complementing the conclusions drawn using chimeric proteins
such as HMGA1a-DBD, a 25 amino acid-long domain has been
identified in the amino-terminus of EBNA that is required for
EBNA1 to transactivate [10]. This domain, termed unique region
1 (UR1), is juxtaposed to the first of EBNA1’s two AT-hooks.
Deletion of UR1 does not abrogate EBNA1’s ability to support the
replication and partitioning of EBV-derived plasmids, but reduces
its transactivation activity to the levels observed with HMGA1a-
DBD [10]. Emphasizing the importance of UR1 in transactiva-
tion, addition of multiple copies of UR1 to HMGA1a-DBD
restores its ability to activate transcription and facilitate the
immortalization of naı ¨ve B-cells [2].
The mechanism by which UR1 contributes to EBNA1’s ability
to activate transcription is unknown. Here, we report that while
UR1 is necessary for EBNA1 to transactivate, it is not sufficient for
transactivation. We demonstrate that UR1 coordinates zinc via
two essential cysteines residues. Chelation of cellular zinc
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activate transcription. Consistent with these results, mutation of
the essential cysteines, prevents the coordination of zinc in vitro,
and also causes a transactivation defect in vivo. By co-immuno-
precipitation and bimolecular fluorescence complementation, we
show that UR1 can interact homotypically, and that this ability
correlates strongly with EBNA1’s ability to activate transcription.
Further, when UR1 dimerizes by coordinating zinc, it facilitates
interactions between dimers of EBNA1, and the latter are required
for EBNA1 to transactivate cooperatively.
We demonstrate that the essential, conserved cysteines within
UR1 are regulated by redox, and that the ability of EBNA1 to
activate transcription is subject to the oxygen levels prevalent in
the environment. At oxygen levels that mimic that found in lymph
nodes, EBNA1 activates transcription from the EBV BamHI-C
promoter in a sustained manner; whereas at higher oxygen levels,
transactivation is dampened rapidly. Exposure of a lymphoblastoid
cell-line (LCL) to mild oxidative stress decreases transcription from
the BamHI-C promoter, a promoter active in latency III.
Reductions are observed in the levels of EBNA2 and LMP1,
genes whose promoters are transactivated by EBNA1 [11,12,13].
Although these changes do not affect the survival of treated cells,
they accumulate in G0/G1. The results reported in this study
provide the first molecular insights into the mechanism by which
EBNA1 activates transcription, and describe environmental
changes that modulate transactivation. We discuss these results
in the context of gene-expression observed in proliferating EBV-
immortalized cells in hypoxic environments such as the lymph
node, and non-proliferating EBV-infected cells observed in the
relatively oxygen-rich periphery.
Results
UR1 is necessary but not sufficient for transactivation by
EBNA1
EBNA1 augments transcription of reporter plasmids bearing the
family of repeats (FR) by both retaining FR-containing DNAs
within cells to increase the number of available transcriptional
templates [10,14], and by directly transactivating FR-dependent
promoters [2,6,10]. While plasmid retention requires the AT-hook
domains of EBNA1 [5], indicated as ATH1 and ATH2 in
Figure 1A, an EBNA1 derivative with a deletion of a.a. 65–89
failed to activate transcription from a chromosomally integrated
FR-dependent transcription reporter. The latter still contains
ATH1 and ATH2, indicating that AT-hooks are irrelevant or
insufficient for transcription activation. This conclusion is
supported by results obtained using a chimera between the
cellular AT-hook protein, HMGA1a, and the DBD of EBNA1.
This chimera, HMGA1-DBD, retains oriP-plasmids as efficiently
as EBNA1, but fails to activate transcription from the same
chromosomally integrated transcription reporter [6]. HMGA1a-
DBD activates transcription from transiently transfected FR-
containing reporter plasmids with approximately 10% the
efficiency of EBNA1 (ibid). Therefore, to distinguish the ability of
EBNA1 derivatives to increase reporter transcription by plasmid
retention versus transactivation, we have compared results
obtained with wild type and mutant EBNA1 proteins to those
obtained with HMGA1a-DBD (Figure 1B). In transient transfec-
tions of C33a cells, using FR-TKp-luciferase as the reporter
plasmid, EBNA1 transactivates the TK-promoter approximately
85-fold over the EBNA1 DNA binding domain (DBD) alone. In
contrast, a mutant of EBNA1 with a.a. 71–88 deleted,
EBNA1D(71–88), activated transcription approximately two-times
as well as the DBD alone. Using the same reporter, HMGA1a-
DBD was observed to activate transcription approximately six-fold
over the DBD. Having confirmed that the UR1 region of EBNA1
was necessary for transactivation to be observed even with
episomal reporter plasmids, we tested if UR1 was sufficient for
transactivation, using an UR1-DBD fusion protein. UR1-DBD
failed to activate transcription from the FR-TKp-luciferase
reporter, and was statistically indistinguishable from the effects
of the DBD alone. Similar results were obtained upon transfection
of EBV-negative BJAB Burkitt’s lymphoma cells with oriP-BamHI-
Cp-luciferase used as the reporter (data not shown). Immunoblot
analyses indicated that the failure of EBNA1D(71–88) and UR1-
DBD to transactivate could not be attributed to lower expression
levels or degradation (Figure S1). In this report, we have examined
the mechanism by which UR1 facilitates transactivation by
EBNA1.
Sequence comparison of the EBNA1 proteins from EBV and
three related gammaherpesviruses indicated that a portion of
UR1, corresponding to a.a. 75–85 of EBV’s EBNA1 protein, was
conserved in all four proteins (Figure 1C). A PSI-BLAST search
conducted using these four conserved sequences matched portions
of several zinc-binding proteins, particularly one-half of a
conserved C4 zinc finger [15] present in the catalytic subunit of
DNA polymerase d from several species (Figure 1C). The matched
sequences contain a pair of cysteine residues separated by two
amino acids, which consist of an aliphatic amino acid and an
invariant glycine. The cysteines are flanked by basic amino-acids,
with an amino-acid whose side-chain contains a hydroxyl or
sulfhydryl group immediately adjacent to the first cysteine. In light
of the UR1’s homology to half a zinc-binding domains, we tested
whether the conserved cysteines residues in UR1 were necessary
for EBNA1’s ability to transactivate FR-dependent promoters. For
this, both cysteines were altered to serines. A schematic of the
mutant protein, EBNA1(CCRSS) is shown in Figure 1D, and by
immunoblot analysis, EBNA1(CCRSS) was observed to be
expressed as well as wild-type EBNA1 (Figure S2). Transactivation
assays indicated that this mutant is severely impaired in its ability
to activate transcription from the FR-TKp-luciferase reporter in
Author Summary
Epstein-Barr virus (EBV) infects human B-cells and immortal-
izes them.Immortalization resultsin diseases thatrangefrom
infectious mononucleosis to malignancies such as lympho-
mas. During immortalization, EBV expresses a small number
of viral genes that modulate cellular proliferation and
differentiation. One of the genes expressed by EBV,
Epstein-Barr nuclear antigen 1 (EBNA1), activates the
expression of the other viral genes required for immortali-
zation. In this report, we have explored the mechanism by
which EBNA1 activates gene expression. We have deter-
mined that EBNA1 uses the micronutrient zinc to self-
associate, and that self-association is necessary for it to
activate gene expression. Further, we have determined that
environmental conditions such as oxygen tension and
oxidative stress modulate EBNA1’s capacity to self-associate,
and therefore to activate gene expression. The gene
expression profile and proliferative phenotype of EBV-
infected cells is known to vary in differing environmental
niches in the human body, such as lymph nodes and in
peripheral circulation. We interpret our results to postulate
that these differences arise as a consequence of varying
oxygen tension in these microenvironments on EBNA1’s
capacitytoactivateviralgeneexpression.Ourfindingscanbe
exploited to devise novel therapeutics against EBV-associat-
ed diseases that target EBNA1 through oxidative stress.
EBNA1: A Zinc-Binding Transactivator
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BJAB cells (data not shown).
In zinc-finger proteins, four cysteines, or a combination of four
cysteines and histidines are used to coordinate zinc [15]. However,
there are no other conserved cysteine or histidine residues present
in the EBNA1 proteins from the four gammaherpesviruses,
making it unlikely that these proteins coordinate zinc as
monomers. Sequences that support multimerization were mapped
previously to a fragment of EBNA1 containing UR1 [16].
Therefore, we postulated that the UR1 regions of adjacent
EBNA1 molecules might coordinate zinc by contributing two
cysteines apiece, and thereby dimerize. This was addressed
experimentally by testing whether UR1 could coordinate zinc,
and if zinc was required for EBNA1 to transactivate.
Zinc is required for EBNA1 to activate transcription
To determine if UR1 coordinates zinc, peptides corresponding
to a.a 58–89 of EBNA1 and EBNA1(CCRSS), indicated as WT
and M in Figure 1D, were tested for their ability to bind
radioactive zinc by a zinc-blot procedure previously used to
identify and characterize several proteins that bind zinc
[17,18,19]. As shown in Figure 2A, the wild-type peptide, but
not the mutant, was observed to bind Zn
65. Parallel blots were
stained with amido-black to confirm that both peptides bound
PVDF with similar efficiencies.
To test whether zinc was necessary for EBNA1 to transactivate,
transfected cells were exposed to TPEN, a chelator known to have
high specificity for zinc. Previously, TPEN has been used to probe
the ability of p53 and other proteins to bind zinc within cells
[20,21,22]. As shown in Figure 2B, TPEN diminished transactiva-
tion by EBNA1 in dose-dependent manner, such that exposure to
5 mM TPEN for 15 hours reduced transactivation by EBNA1 to
approximately 4% of the untreated control. In contrast, a higher
level of TPEN, approximately 40 mM, was required to affect the
function of p53 [21]. EBNA1’s ability to transactivate was also
reduced in the presence of 1.5 mM and 3 mM TPEN (data not
shown). Because exposure to TPEN for shorter or similar lengths of
time has been shown to induce apoptosis in some cell-lines [20], a
cell-cycle analysis was performed on TPEN-treated transfected
C33a cells, and is summarized in Figure 2B. C33a cells were more
resistant to TPEN-induced apoptosis than HeLa cells, BJAB cells
and lymphoblastoid cell lines (data not shown). At 45 mM TPEN, a
substantial sub-G1 peak was observed. In contrast, at lower
concentrations of TPEN the cell-cycle profiles of TPEN-treated
cells were similar to those observed for untreated cells. Immunoblot
analysis indicated that TPEN did not decrease transactivation by
inhibiting the synthesis, or inducing the degradation of EBNA1
(Figure 2B). The effect of TPEN was also examined on a co-
transfected CMV-EGFP reporter plasmid, and found to not
significantly change the fraction of live, GFP-positive cells, or the
mean fluorescence index of these cells. To investigate the possibility
that transcription from the TK promoter require other zinc-
dependent transcription factors affected by TPEN, we examined
whether TPEN altered transactivation by a chimeric protein in
which the DBD was fused to the acidic activation domain of VP16
[23] (DBD-VP16). DBD-VP16, which lacks the N-terminal 450 a.a
of EBNA1, activates transcription from the FR-TKp-luciferase
reporter (Figure 2C), and this activation is not reduced by treatment
with 5 mM TPEN. Thus, exposure to TPEN specifically reduces the
ability of EBNA1 to transactivate the FR-dependent transcription
reporter plasmids. Next, we tested whether inhibition by TPEN was
reversible by the subsequent addition of zinc or other metal ions
(Figure 2D). Transfected cells were treated with 5 mM TPEN for
15 hours, following which zinc or other metal ions were added for
an additional 15 hours prior to analysis. It was observed that
addition of Zn
2+ or Cd
2+ effectively restored transactivation, in
contrast to Mg
2+,C a
2+,M n
2+ and Fe
2+ (Figure 2D). Addition of
Zn
2+ or Cd
2+ did not affect basal transcription from the FR-TKp-
luciferase reporter, or transactivation of this reporter by DBD-VP16
(data not shown). The ability of zinc to restore EBNA1-dependent
transactivation in TPEN-treated cells was concentration dependent,
and did not affect expression from a co-transfected CMV-EGFP
reporter (Figure S3).
The amino-terminal 450 amino acids of EBNA1 do not
squelch transactivation by EBNA1
We initially postulated that UR1 might facilitate a zinc-
dependent interaction between EBNA1 and a cellular transcrip-
tion co-activator. To identify such proteins, a yeast two-hybrid
screen was performed using the first 94 amino acids of wild-type
EBNA1 as the bait protein against a cDNA library from HeLa
cells, a cell-line in which EBNA1 has been observed to activate
transcription. No protein identified in this screen associated
specifically with the bait protein, but not an UR1-deleted
derivative (data not shown). In an effort to test our hypothesis
that UR1 associates with cellular transcription factors, we tested
whether co-expression of EBNA1’s amino-terminal 450 a.a.
interferes with EBNA1’s ability to activate transcription from an
FR-dependent reporter plasmid, by squelching its interaction with
putative cellular co-activators or general transcription factors
[24,25]. As shown in Figure 3, co-transfecting increasing amounts
of an expression plasmid encoding a fusion between the first 450
a.a. of EBNA1 and the DNA binding domain of the BPV-1 E2
protein, 3xF-EBNA1(1-450)-E2DBD, did not affect the ability of
Figure 1. Two conserved cysteines in EBNA1’s UR1 domain are essential for transactivation. (A) Schematic representation of the EBNA1
derivatives used in this study. The positions of the EBNA1’s AT-hook domains (ATH1 & ATH2), UR1, DBD are indicated. The NLS spans from a.a 379–
386. The EBNA1 derivatives used in this study contain a shortened glycine-alanine repeat that is 15 a.a. in length. EBNA1D(71-88) contains a deletion
of a.a. 71–88 within the UR1 region. The HMGA1a-DBD protein contains the full length HMGA1a protein fused to the NLS, and the DBD. UR1-DBD
contains a.a. 65–89 fused to a.a. 379–641 of EBNA1. The EBNA1(CCRSS) protein is described in detail below. (B) Transactivation of the FR-TKp-
Luciferase reporter plasmid by the derivatives of EBNA1 shown in Figure 1A. C33a cells were individually co-transfected with the FR-TKp-Luciferase
reporter plasmid, and expression plasmids for the indicated EBNA1 derivatives as described in the Methods section. Luciferase assays were performed
at 48 hours post-transfection. Luciferase activity is expressed as fold over the level observed with when DBD is used as the effector protein. The data
represents the average of at least three experiments for each EBNA1 derivative. (C) The UR1 region of EBNA1 is conserved in the EBNA1 orthologs of
EBV-like gammaherpesviruses. Amino acids 75–85 of EBNA1 from EBV strain B95-8 (accession no. CA24816) (red) are aligned with the corresponding
regions from EBNA1 proteins of other gammaherpesviruses (accession nos. YP_067973, BAB03281, AAA66373) (blue), and a portion of a C4 zinc-
finger contained in the catalytic subunit of DNA polymerase d from Xenopus laevis (accession no. NP_001087694), Danio rerio (accession no.
CAM46996), Nematostella vectensis (accession no. XP_001641357), Drosophila mojavensis (accession no. XP_002008314), and Homo sapiens (accession
no. P28340), identified by BLAST searches. Three or more alike amino-acids in the aligned sequences are shaded the same color. The Genbank
accession number for each protein is indicated adjacent to it. (D) Schematic depiction of EBNA1 and the EBNA1(CCRSS) mutant, in which conserved
cysteines at position 79 and 82 are mutated to serine. The sequences of wild-type (WT), and mutant (M) peptides used in this study are also shown.
doi:10.1371/journal.ppat.1000469.g001
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reporter, over the pcDNA3 control. In contrast, co-transfecting a
DBD expression plasmid decreased the expression observed from
FR-TKp-luciferase, by expressing a protein that competes
efficiently with EBNA1’s ability to bind FR [26]. While 3xF-
EBNA1(1-450)-E2DBD does not interfere with the function of
wild-type EBNA1, it retains the ability to activate transcription
from a TKp-luciferase reporter plasmid containing twenty E2-
binding sites (Figure S4), and this transactivation is sensitive to
treatment with 5 mM TPEN (Figure S5). Thus, the inability of
3xF-EBNA1(1-450)-E2DBD to squelch transactivation of FR-
TKp-luciferase by EBNA1 is not because it is incapable of
activating transcription via a mechanism similar to that used by
EBNA1.
Some proteins transactivate by directly altering DNA template
structure. For example, the prototypic cellular AT-hook protein,
Figure 2. Zinc is coordinated by EBNA1’s UR1 domain, and is required for EBNA1 to transactivate. (A) Evaluation of Zinc
65 binding by
the wild type (WT) and mutant (M) UR1 peptides. The indicated amounts of WT and M peptides were dot-blotted on a 0.2 mM PVDF membrane, and
probed with radioactive zinc (,50 mCi) as described in the Methods section. Washed membranes were dried and visualized using a Phosphorimager.
WT peptide was observed to bind Zn
65 in a concentration-dependent manner. In contrast, the M peptide failed to bind zinc. To confirm that both
peptides bound the PVDF membrane, a blot prepared in parallel was dried and stained using Amido Black. (B) The metal chelator TPEN reduces the
ability of EBNA1 to transactivate FR-TKp-Luciferase. C33a cells were co-transfected the FR-TKp-Luciferase reporter plasmid, an EBNA1-expression
plasmid, and a CMV-EGFP expression plasmid. Cells were treated with the indicated levels of TPEN at the time of transfection, and harvested 15 hours
later. Harvested cells were analyzed by flow cytometry to determine the fraction of live-transfected cells, the level of EGFP expression in that fraction.
For cell-cycle analysis, the cells were fixed and then PI-stained. An aliquot of harvested cells were used to determine the expression level EBNA1 by
immunoblot upon treatment with the indicated amounts of TPEN, shown as an inset in the graph. The rest of the cells were processed to determine
luciferase activity, which is expressed as a percent of the luciferase activity observed in the absence of TPEN treatment, and shown in the grey bars.
The open bars indicate the percent of live EGFP-positive cells at each concentration of TPEN. The asterisks indicate that the significantly lower levels
of luciferase activity were observed in the presence of 5, 15 and 45 mM TPEN (p,0.05, Wilcoxon rank-sum test). The cell-cycle profile of TPEN-treated
and control cells was obtained for one experiment, and is shown below the graph. (C) TPEN does not affect transactivation by DBD-VP16. C33a cells
were co-transfected with the FR-TKp-Luciferase reporter plasmid, and expression plasmids for DBD, and DBD-VP16. Some DBD-VP16 transfected cells
were treated with the indicated amounts of TPEN at the time of transfection, and analyzed 15 hours later to determine the fraction of live-transfected
cells, and the level of luciferase expression. The activity observed with DBD-VP16 in the absence and presence of TPEN is expressed as the fold-over
the luciferase level observed with DBD alone. (D) Zinc and Cadmium reverse TPEN-mediation inhibition of transactivation by EBNA1. C33a cells were
co-transfected with the FR-TKp-Luciferase reporter plasmid, an EBNA1 expression plasmid, and a CMV-EGFP expression plasmid, and treated with
5 mM TPEN at the time of transfection. Fifteen hours post-TPEN addition, 5 mM of Zn (CH3COO)2, Cd(CH3COO)2, CaCl2, MgSO4, MnCl2, or Fe(CH3COO)2,
was added to the cells for an additional 15 hours. Cells were harvested and analyzed by flow cytometry to determine the level of live-transfected
cells, followed by determination of luciferase activity. The relative activation is shown in the grey bars, and is expressed as a percent of the luciferase
activity observed in the untreated sample.
doi:10.1371/journal.ppat.1000469.g002
EBNA1: A Zinc-Binding Transactivator
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formation [8,27]. HMGA1a, p53, Ikaros, and other proteins are
also known to homotypically interact, loop intervening DNA, and
thereby juxtapose a distal enhancer to a promoter [28,29,30].
EBNA1 has AT-hooks, and is known to loop oriP-DNA [31,32].
Looping activity correlates to domains in the first 450 a.a. of
EBNA1, particularly UR1 [16,33,34]. Therefore, we tested
whether UR1 functions as a zinc-dependent self-association
domain.
UR1 is a zinc-dependent self-association domain
Co-immunoprecipitation was used to test if EBNA1(1-450)-
E2DBD associates with wild-type EBNA1, and EBNA1(CCRSS).
For this, EBNA1(1-450)-E2DBD, which is amino-terminally
tagged with a 3xFLAG epitope, was co-expressed in 293 cells
along with EBNA1 or EBNA1(CCRSS). Lysates were incubated
with a monoclonal anti-Flag antibody linked to sepharose beads,
and examined by immunoblot. As shown in Figure 4A, EBNA1
was co-precipitated with EBNA1(1-450)-E2DBD using the anti-
FLAG antibody. In contrast, EBNA1(CCRSS) was never
observed to associate with EBNA1(1-450)-E2DBD. Immunoblots
using anti-EBNA1 antibody indicated that EBNA1 and EB-
NA1(CCRSS) were expressed equivalently in lysates.
Having determined that the amino-terminal 450 a.a. of EBNA1
could self-associate if the sequence of UR1 was not altered, we
tested whether UR1 was sufficient to mediate homotypic
interactions using bimolecular fluorescence complementation
[35]. For this, UR1 was fused to amino acids 2-154 of EYFP, or
to amino acids 155-238 of EYFP. Expression plasmids were co-
transfected into 293 cells, and examined by fluorescence
Figure 3. EBNA1(1-450)-E2DBD does not squelch transactiva-
tion by EBNA1. C33a cells were co-transfected with the FR-TKp-
Luciferase reporter plasmid, and control vector pcDNA3 (dark grey
bars), an expression plasmid for EBNA1(1-450)-E2DBD (light grey bars),
or an expression plasmid for DBD (open bars, in the amounts indicated
below each bar. Cells were harvested at 48 hours post-transfection,
normalized by flow cytometry for the number of live-transfected cells,
and analyzed for luciferase activity, which is expressed as percent
luciferase activity relative to the activity obtained by co-transfection
with the same amount pcDNA3.
doi:10.1371/journal.ppat.1000469.g003
Figure 4. EBNA1 can self-associate through its UR1 domain. (A) The amino-terminal 450 amino-acids of EBNA1 can self-associate. 293 cells
were co-transfected with expression vectors for 3xF-EBNA1(1-450)-E2DBD, and either EBNA1 or EBNA1(CCRSS). 48 hours post-transfection, lysates
were prepared from harvested cells. EBNA1(1-450)-E2DBD was immunoprecipitated using the M2 monoclonal anti-FLAG antibody conjugated to
sepharose beads. Immunoprecipitates were separated on an 8% SDS-PAGE gel, transferred to PVDF membranes and immunoblotted using M2
mouse monoclonal anti-FLAG antibody (a-FLAG/a-FLAG), or rabbit polyclonal antibodies directed the EBNA1 DBD (a-FLAG/a-DBD). 5% of the lysates
were directly immunoblotted for EBNA1 or EBNA1(CCRSS) (5% lysate/a-DBD). (B) Self-association of UR1 can be detected by bimolecular
fluorescence complementation: 293 cells were transfected with expression plasmids for (A) EYFP(2-154) and EYFP(155-238), or (B) & (C) expression
plasmids for UR1-EYFP(2-154) and UR1(155-38). Transfected cells were treated with (B) vehicle, or (C) 80 mM 1,10-phenanthroline. 48 hours after
transfection, cells were visualized by fluorescence for EYFP (YFP) or by light microscopy (DIC). The scale bars indicate a length of 10 microns. The
fraction of fluorescent cells observed under each condition in five independent measurements is shown along with the standard deviation. The
number of fluorescent cells observed with the UR1-containing EYFP derivatives is significantly greater than the number seen with the EYFP
derivatives by themselves (p,0.01). A significant decrease in the number of florescent cells is observed after treatment with 1,10-phenanthroline
(p,0.05) when compared to the untreated cells.
doi:10.1371/journal.ppat.1000469.g004
EBNA1: A Zinc-Binding Transactivator
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parental plasmids expressing both halves of EYFP (Figure 4B),
or with each of the UR1 plasmids transfected singly (data not
shown), the UR1 fusions complemented each other (Figure 4B).
The ability of zinc chelators to disrupt complementation was tested
using 1,10-phenanthroline, which has been used widely to dissect
the role of zinc association with various proteins [36,37]. TPEN
could not be used for this experiment because even low levels of
TPEN cause 293 cells to dissociate from the coverslip. Transfected
cells were treated with 80 mM 1,10-phenanthroline for 24 hours,
and then examined by microscopy. Treatment of transfected cells
with 80 mM 1,10-phenanthroline for 24 hours caused a large
decrease in the number and intensity of EYFP-positive cells
(Figure 4B). These results indicate that UR1 can self-associate in a
manner dependent on metal ions.
The nature of self-association mediated by UR1
While the previous results indicate that UR1 can mediate
dimerization as evaluated by bimolecular fluorescence comple-
mentation, they do not distinguish between direct association and
indirect association mediated by a cellular protein. If zinc
coordination results in direct association, it is relevant to consider
that in addition to forming dimers, pairs of cysteines can form
trimers and tetramers, as observed in the GAL4 DBD [38], or in
the RING finger [39]. To distinguish between such multimeric
forms, we examined the migration properties of the wild-type UR1
peptide in the presence and absence of zinc by size exclusion
chromatography. After establishing conditions to observe a highly
reproducible elution profile for molecular weight standards, the
peptides were examined by chromatography in the presence and
absence of 1 mM zinc sulfate. The results of this analysis are
shown in Figure 5A. The apparent molecular weight (MW)
calculated from the peak retention time for the peptides in the
absence of zinc were close to their theoretical MWs. WT peptide
eluted as a single peak in the absence of zinc with an apparent
molecular weight of 3.6 kD (Figure 5A). When the wild-type
peptide was analyzed in the presence of zinc, two peaks were
observed: 1) a small peak, representing approximately 5% of the
total, migrated at an apparent molecular weight of 1.6 kD; 2) a
large peak, consistent with size of a dimer that migrated at a
apparent molecular weight of 6.8 kD. The presence or absence of
zinc had no effect on the retention time of the mutant peptide
(data not shown). These data indicate that at least in the context of
a peptide, UR1 dimerizes in the presence of zinc.
The ability of UR1 to dimerize indicates that either EBNA1
contains a second intra-molecular dimerization domain at its N-
terminus, or that dimers of EBNA1 may form larger inter-
molecular complexes through UR1. To distinguish between these
two possibilities, attempts were made using cross-linkers or Blue
native electrophoresis to resolve complexes formed by wild-type
EBNA1 within transfected cells. In such gels, we could not
distinguish between multimers of EBNA1 dimers, and EBNA1
associated with cellular proteins that interact with EBNA1, such as
p32/TAP/gC1qR [40], Importin-a/Rch1 [41], p40/EBP2 [42],
and Brd4 [43] (data not shown).
Therefore, we resorted to an alternative approach in an effort to
distinguish between intra-molecular and inter-molecular dimer-
ization mediated by UR1. This approach was chosen on the basis
of two alternative hypotheses for the mechanism by which UR1
dimerization may contribute to transactivation. In the first, it was
hypothesized that UR1 was necessary to form intra-molecular
dimers that are essential for transactivation. Alternatively, it was
hypothesized that inter-molecular dimerization by UR1 was
necessary to form a structured array of EBNA1 bound to FR,
and that such arrays were necessary for transactivation. These two
hypotheses can be distinguished by examining how transactivation
by wild-type EBNA1 or EBNA1(CCRSS) varies with the number
of EBNA1-binding sites. If UR1 is necessary to form intra-
molecular dimers required for transactivation, then it is predicted
that EBNA1(CCRSS) will transactivate poorly relative to wild-
type EBNA1, independent of the number of binding sites. In
contrast, if UR1 is necessary to form inter-molecular dimers
required for transactivation, then it is predicted that for a single
binding site or a small number of binding sites, EBNA1(CCRSS)
will transactivate equivalently to EBNA1, with a defect in
transactivation being exposed as the number of binding sites is
increased. Therefore, the ability of wild-type EBNA1 and
EBNA1(CCRSS) to transactivate a series of reporter plasmids
containing one, three, five, seven, ten and 20 binding-sites was
examined under conditions previously determined to be optimal to
observe cooperative transactivation (Figure 5B).
The white bars in Figure 5B indicate the level of transactivation
predicted with increases in the number of binding sites, assuming a
simple additive relationship between the two. In contrast, as shown in
Figure5B,andobservedpreviously[3,44],transactivationbyEBNA1
(black bars) is strongly cooperative, with a synergism that is
proportional to the number of binding sites. Under optimal
conditions, EBNA1 bound to 20 binding-sites transactivates
approximately 150-fold over EBNA1 bound to a single binding-site,
and it is important to note that the latter is reproducibly two to three-
fold over what is observed in the absence of EBNA1. Transactivation
by EBNA1(CCRSS) (gray bars) could not be distinguished
statistically from wild-type EBNA1 for reporter plasmids containing
one, three or five binding sites. We note that for such small numbers
of binding sites, wild-type EBNA1 does not display significant
synergism. In contrast to wild-type EBNA1, at higher numbers of
binding sites, EBNA1(CCRSS) does not transactivate cooperatively.
We interpret these results to indicate that the major contribution of
UR1 toward EBNA1’s ability to transactivate is by facilitating
cooperativity; the latter being more consistent with inter-molecular
interactions than intra-molecular dimerization.
When the correlation between transactivation and number of
binding sites is fit to a sigmoidal dose-response curve by non-linear
regression, strong positive cooperativity is observed for wild-type
EBNA1, with a Hill coefficient (HC) of 3.960.48 (Figure 5C), and
a goodness of fit (R
2) of 0.9996. No cooperativity is observed when
transactivation by EBNA1(CCRSS) is fit to the same sigmoidal
dose-response curve (HC=31.77640698), and the data fit this
model poorly (R
2=0.9459) (Figure 5D).
In conjunction with other results presented here (Figure 4 and
Figure 5A), it is concluded that UR1 facilitates cooperative
transactivation by mediating inter-molecular interactions between
adjacent EBNA1 dimers bound to FR. It remains to be
determined whether such cooperative interactions facilitate
architectural changes at the promoter, or association with a
coactivator. We note that if a multimerization-dependent
coactivator mediates transactivation, it is equally inefficient in
associating with wild-type EBNA1 and EBNA1(CCRSS) when
these proteins are bound to one, three or five binding-sites.
While our data favor a role for UR1 in inter-molecular
associations over intra-molecular dimerization, we reiterate that
either interaction remains dependent on the ability of two
cysteines residues within UR1 to coordinate zinc. The ability of
cysteines to associate with zinc is regulated by their redox status.
Reduced cysteines can coordinate zinc, whereas oxidized cysteines
cannot. For zinc-finger proteins, and other transcription factors, it
has been observed that the redox state of cysteine modulates
activity.
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Transactivation by AP-1, NFkB, and zinc-binding proteins such
as p53 and Egr-1 is modulated by intracellular redox, and is
increased two to three-fold by over-expression of redox factor 1
(Ref-1/APE1) [45,46,47,48,49]. The oxidation status of zinc-
coordinating cysteines regulates the activity of several zinc-finger
transcription factors, such as Sp1, Egr-1 and steroid hormone
receptors [45,50,51,52], because oxidation of sulfhydryl groups
(-SH) results in the progressive generation of sulfenic acid (-SOH),
sulfinic acid (-SO2H) and sulfonic acid (-SO3H), none of which can
coordinate zinc. Therefore cysteine oxidation alters the structure,
and consequentially the function of zinc-binding proteins [53].
Menadione, a redox-reactive p-quinone has been used to study the
effect of redox on proteins containing reactive cysteines, including
Figure 5. UR1-mediated self-interaction is required for EBNA1 to transactivate cooperatively. (A) Size-exclusion chromatography of the
wild-type UR1 peptide indicates zinc-dependent dimerization. WT peptide was subjected to HPLC size-exclusion chromatography, as described in the
Methods section, in the absence of zinc (red), or in the presence of 1 mM zinc sulfate in the buffer (green). The retention time is indicated above each
peak, and the apparent molecular weight calculated from the retention time is shown in parentheses. The elution profile of molecular weight markers
is shown in gray. The known molecular weight of each marker is indicated above the peak, with the observed retention time shown in parentheses.
(B) Cooperative transactivation by EBNA1 is UR1-dependent. C33a cells were co-transfected individually with TKp-luciferase reporter plasmids
containing one, three, five, seven, ten, or 20 EBNA1 binding sites in FR along with an expression plasmid for EBNA1 or EBNA1(CCRSS). Cells were
harvested at 48 hours post-transfection, normalized by flow cytometry for the number of live-transfected cells, and analyzed for luciferase activity,
which is expressed as luciferase activity fold-over the activity obtained by co-transfection with vector control. The white bars indicate the predicted
levels of transactivation for EBNA1 if it increased additively with increasing numbers of binding sites. The transactivation observed with EBNA1 is
indicated by the black bars, and transactivation observed with EBNA1(CCRSS) is indicated by the gray bars. For reporter plasmids containing up to
three binding sites, EBNA1 and EBNA1(CCRSS) transactivated equivalently. A small difference was observed for a reporter plasmid with five binding
sites, and this difference was greatly accentuated for reporter plasmids containing seven, ten, and 20 binding sites. (C) Cooperative transactivation by
EBNA1 fits a sigmoidal dose-response model by non-linear regression analysis. The fold transactivation by EBNA1 observed in (5B) was analyzed for
cooperativity as described in the Materials & Methods, and found to fit a sigmoidal dose-response model well, as indicated by the goodness of fit (R
2).
Positive-cooperativity is inferred from the positive Hill coefficient (HC). (D) EBNA1(CCRSS) does not activate transcription cooperatively. The fold
transactivation observed for EBNA1(CCRSS) was fit to the same sigmoidal dose-response model used in 5C. The low R
2 indicates that transactivation
by EBNA1(CCRSS) poorly fits this model. In addition, the large standard deviation observed for the HC also indicates a lack of cooperative
transactivation.
doi:10.1371/journal.ppat.1000469.g005
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coordination is required for EBNA1 to activate transcription, we
tested whether exposure to menadione affected transactivation.
C33a cells co-transfected with an EBNA1-expression plasmid and
the FR-TKp-luciferase reporter plasmid were split six hours post-
transfection and exposed to increasing levels of menadione for
18 hours prior to analysis. Menadione reduced transactivation in a
dose-dependent manner (Figure 6A), without affecting expression
of a co-transfected CMV-EGFP reporter plasmid (data not
shown). Although transactivation was reduced to as little as
20%, no profound change in the cell-cycle profile of transfected
cells was observed upon menadione treatment at concentrations
up to 2 mM (Figure 6A). The highest concentration of menadione
used here is considerably lower than concentrations of menadione
used to induce apoptosis via oxidative stress [56]. A similar 50%
decrease in transactivation was observed upon treatment of
transfected cells with 150 mM of the mild oxidant paraquat
(Figure S6). Menadione did not affect transactivation by DBD-
Figure 6. Transactivation by EBNA1 is sensitive to oxidative stress, and is augmented by over-expression of APE1/Ref-1. (A)
Menadione reduces the ability of EBNA1 to transactivate FR-TKp-Luciferase. C33a cells were co-transfected the FR-TKp-Luciferase reporter plasmid,
and an EBNA1-expression plasmid. Cells were treated with the indicated levels of menadione six hours post-transfection, and harvested 18 hours
later. For cell-cycle analysis, an aliquot of cells was fixed and then PI-stained. The rest of the cells were processed to determine luciferase activity,
which is expressed as a percent of the luciferase activity observed in the absence of menadione treatment, and shown in the grey bars. The cell-cycle
profiles of menadione-treated and control cells were obtained for one experiment, and are shown below the graph. The asterisks indicate statistical
significance (p,0.05) compared to control. (B) Menadione affects the ability of UR1 to support bimolecular fluorescence complementation. C33a cells
were transfected with expression plasmids for A) EYFP(2-154) and EYFP(155-238), or B) & C) expression plasmids for UR1-EYFP(2-154) and UR1(155-
238). Transfected cells were treated with vehicle alone, or 0.6, 1.4 and 2.0 mM menadione six hours after transfection. Cells were visualized by
fluorescence for EYFP (YFP) or by light microscopy (DIC) after 18 hours of menadione treatment. The scale bars indicate a length of 10 microns. The
fraction of fluorescent cells observed for each menadione concentration in five independent measurements is shown along with the standard
deviation. The p-values indicate statistical significances calculated using the Wilcoxon rank-sum test upon a pair-wise comparison to untreated cells.
p-values lower than 0.05 indicate significance. (C) Over-expression of Ref-1/APE1 augments transactivation by EBNA1. C33a cells were transfected
with an EBNA1 expression plasmid, and increasing amounts of an expression plasmid for Ref-1/APE1 along with the FR-TKp-luciferase reporter
plasmid. Luciferase levels were evaluated 48 hours post-transfection, and are expressed as a fraction of transactivation observed in the absence of
Ref-1/APE1, which was set to be 100%. The asterisks indicate statistical significance (p,0.05) compared to control. (D) Over-expression of Ref-1/APE1
ameliorates the effect of menadione on EBNA1 mediated transactivation. C33a cells were transfected with an EBNA1 expression plasmid, and either
1 mg of a Ref-1/APE1 expression plasmid or empty vector control plasmid in addition to the FR-TKp-luciferase reporter plasmid. Six hours post-
transfection, the cells were split and half the cells were treated with 1.4 mM of menadione. Luciferase levels were evaluated 24 hours post-
transfection. p values are indicated in the figure.
doi:10.1371/journal.ppat.1000469.g006
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unlikely to have inactivated components of the basal transcription
apparatus used at the HSV-1 Tk promoter. Bimolecular
fluorescence complementation was used to examine whether
oxidative stress impaired the ability of UR1 to support
dimerization, which is essential for transactivation. Cells trans-
fected with the UR1-EYFP derivatives described above were split
six hours post-transfection, and then exposed to increasing
concentrations of menadione for 18 hours prior to analysis by
fluorescence microscopy. At concentrations of menadione above
0.6 mM, a statistically significant reduction in the fraction of
fluorescent cells was observed (Figure 6B), with a concomitant
decrease in fluorescence intensity (Figure 6B and data not shown).
In the absence of menadione, approximately 20 fluorescent cells
were observed for every 100 adherent cells. In the presence of
1.4 mM menadione, where a 50% reduction in transactivation was
observed (Figure 6A), approximately five fluorescent cells were
observed for every 100 adherent cells. Together, these results
indicate that the reduction in transactivation observed upon
oxidative stress correlates with an impaired ability of UR1 to
support dimerization.
During oxidative stress, thioredoxin directly reduces cysteines
on target transactivators, or increases the amount of reduced Ref-
1/APE1 available to reduce cysteines on target proteins [57,58].
One characteristic of cysteines that are reduced by Ref-1/APE1 is
their close juxtaposition to lysine and/or arginine residues. The
conserved cysteines in UR1 lie in such a connotation (Figure 1C).
It was therefore tested whether over-expression of Ref-1/APE1
would affect EBNA1’s ability to transactivate. For this, C33a cells
were co-transfected with an EBNA1-expression plasmid, the FR-
TKp-luciferase reporter plasmid, and increasing amounts of an
expression plasmid for Ref-1/APE1. This analysis, shown in
Figure 6C, indicated that over-expression of Ref-1/APE1
increased the ability of EBNA1 to activate transcription by as
much as 3-fold, a magnitude of increase similar to its effect on
other redox-sensitive transcription factors [45,46,47,48,49]. Ref-
1/APE1 did not increase transactivation by DBD-VP16 from the
same reporter, and did not affect expression of either DBD-VP16
or EBNA1 (data not shown). Because Ref-1/APE1 augmented
EBNA1’s ability to transactivate, we tested whether over-
expression of Ref-1/APE1 would ameliorate the effect of oxidative
stress induced by menadione. For this, C33a cells were transfected
with an EBNA1-expression plasmid, the FR-TKp-luciferase
reporter plasmid and either an APE1-expression plasmid, or
empty vector control. Cells were split six hours post-transfection,
and one-half treated with 1.4 mM menadione. As is shown in
Figure 6D, cells that over-express Ref-1/APE1 are resistant to
menadione treatment. Similarly, over-expression of Ref-1/APE1
reversed the effect of 150 mM of paraquat on EBNA1 (Figure S8).
Thus, as reported for several other viral and cellular transactiva-
tors, Ref-1/APE1 also facilitates EBNA1’s ability to transactivate
by modulating redox.
Transactivation by EBNA1 is sustained under hypoxic
conditions
B-cells infected latently by EBV reside in the periphery and
internal body compartments such as lymph nodes and tonsilar
tissue. These compartments differ considerably in the availability
of O2, so that the oxygen partial pressure (pO2) is approximately
80 torr (10.5% O2) in the periphery while the pO2 in lymph ranges
between 20–40 torr (2.5%–5% O2) [59,60], or lower [61]. The
latently infected cells in these compartments are dramatically
different, with distinct patterns of viral gene expression. Cells in
the lymph node express all the EBV genes necessary to drive
proliferation of latently-infected cells (latency III). In contrast,
latently-infected cells in the periphery are largely quiescent, and do
not express any viral proteins, with the exception of EBNA1 when
cells divide (latency 0/I) [62,63]. While it is clear that there are
epigenetic changes on the EBV genome associated with these two
distinct patterns of latency [4,64,65], the contributions of viral
proteins toward this ‘‘imprinting’’ is unknown. Transactivators,
such as NFkB, Egr-1, p53 and AP-1, whose activities are increased
by over-expression of Ref-1/APE1, are also more active under
hypoxic conditions [47,66,67,68]. We therefore tested the effect of
hypoxia on EBNA1’s ability to transactivate. For this, C33a cells
were co-transfected with an EBNA1-oriP expression plasmid, and
the oriP-BamHI-Cp-luciferase reporter plasmid. Transfected cells
were split six hours post-transfection, and incubated in parallel
under normoxic (21% O2) and hypoxic (4% O2) conditions for six
days, and it is emphasized that the latter mimic the pO2 found in
lymph nodes [59,60,61]. The expression of luciferase was
measured daily during this time-course, and the amount of
replicated oriP-BamHI-Cp-luciferase reporter plasmid was mea-
sured at the end of six days. At the earliest measurement point,
48 hours post-transfection, the levels of luciferase were approxi-
mately 25% higher in cells maintained under hypoxia than cells
maintained in normoxic conditions (Figure 7A). For both
conditions, the level of luciferase expression decreased over time;
however, the rate of decrease was more rapid under normoxic
conditions than hypoxic conditions. As a consequence of the
difference in rates, by six days post-transfection, the average
amount of luciferase expressed in hypoxic cells was 3.5-fold the
level expressed in normoxic cells (Figure 7A). Southern blots
performed to quantify the level of replicated oriP-BamHI-Cp-
luciferase reporter plasmids six days post transfection, indicated
equivalent numbers of plasmids per cell under both conditions
(Figure 7B). The latter result indicates that differences in luciferase
expression between hypoxic and normoxic conditions cannot be
attributed to differences in EBNA1’s association with its cognate
binding sites in oriP under these two conditions. To confirm this,
an expression plasmid for DBD-VP16 was co-transfected with FR-
TKp-luciferase into C33a cells that were subsequently maintained
at hypoxic or normoxic conditions for 72 hours. No difference in
luciferase expression was detected (Figure 7C), reiterating the
conclusion that the difference in luciferase activity under normoxic
and hypoxic reflects a difference in EBNA1’s ability to activate
transcription under these two conditions, and not its ability to bind
FR or support oriP replication and maintenance. These experi-
ments provide evidence that UR1 can act as a molecular sensor
that modulates EBNA1’s ability to activate transcription in
response to environmental conditions.
To determine the relevance of these observations for EBV gene-
expression within immortalized cells, we examined the effects of
oxidative stress on transcription from the BamHI-C promoter in a
LCL.
The effect of oxidative stress on BamHI-Cp transcription
in a lymphoblastoid cell-line
These experiments were conducted in an LCL, NOLA-1,
immortalized using the B95-8 strain of EBV. In preliminary
experiments, it was observed that while treatment of NOLA-1 with
1.4 mM menadione was toxic within 18 hours, treatment with
150 mM paraquat was not toxic for at least 72 hours. Therefore,
NOLA-1 cells were treated with 150 mM paraquat. Aliquots of
cells were removed at 48 and 72 hours to assay transcription from
the BamHI-Cp promoter by real-time PCR, the results of which
are shown in Figure 8A. Within 48 hours of treatment with
150 mM paraquat, the level of BamHI-Cp transcripts was observed
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cells. This decrease was significant, with a p-value of less than 0.01.
After 72 hours of treatment, a further decrease in the level of
BamHI-Cp transcripts was observed, such that it was approx-
imately 40% the level observed in control cells (p,0.01).
Treatment with paraquat did not decrease the viability of cells
as estimated by mitochondrial respiration for up to 72 hours (data
not shown). In addition, a cell-cycle analysis indicated that
paraquat treatment did not increase the fraction of sub-G1 cells,
although paraquat-treated cells clearly accumulated in G0/G1
after 72 hours of exposure (Figure 8A). Staining with Annexin V
and propidium iodide indicated a small increase in the numbers of
doubly-positive necrotic cells, and annexin V-positive apoptotic
cells as a consequence of paraquat treatment. However, we
emphasize that the majority of cells remained doubly-negative
(Figure 8B). Therefore, the decreases observed in BamHI-Cp
transcription do not result from cellular necrosis or apoptosis.
The decrease in BamHI-Cp transcription was confirmed by
examining protein levels for EBNA2 and LMP1 by immunoblot,
along with the levels of EBNA1. This analysis is shown in
Figure 8B. No significant decrease in EBNA1 protein levels were
observed after 72 hours of exposure to paraquat, indicating that
the decrease in BamHI-Cp transcription does not result from a
reduction in EBNA1. At the same time-point, an approximately
50% decrease in the levels of EBNA2 and LMP1 were observed.
Both these proteins have substantially shorter half-lives than
Figure 7. Hypoxic conditions prolong EBNA1’s capacity to transactivate. (A) Transactivation by EBNA1 is sustained under hypoxic
conditions. C33a cells were co-transfected with an EBNA1-oriP expression plasmid and the oriP-BamHI-Cp-luciferase reporter plasmid. Transfected
cells were split six hours post-transfection, and grown under normoxic (filled circles) or hypoxic conditions (filled squares). Luciferase expression was
measured at the indicated time-points, and is expressed relative to the luciferase expression observed under normoxic conditions 48 hours post-
transfection. (B) Oxygen levels do not affect oriP-plasmid replication and maintenance. A Southern blot was performed to examine the levels of
replicated (DpnI-resistant) oriP-BamHI-Cp-luciferase plasmid recovered after six days under normoxic or hypoxic conditions. The arrowhead indicates
replicated, full-length oriP-BamHI-Cp-luciferase. (C) Environmental oxygen levels do not alter the activity of DBD-VP16. C33a cells were transfected
with a DBD-VP16 expression plasmid and the FR-TKp-luciferase reporter plasmid. Luciferase activity was measured three days post-transfection in
cells exposed to normoxic or hypoxic conditions.
doi:10.1371/journal.ppat.1000469.g007
EBNA1: A Zinc-Binding Transactivator
PLoS Pathogens | www.plospathogens.org 11 June 2009 | Volume 5 | Issue 6 | e1000469EBNA1: A Zinc-Binding Transactivator
PLoS Pathogens | www.plospathogens.org 12 June 2009 | Volume 5 | Issue 6 | e1000469EBNA1 [69,70,71], and at least for EBNA2 the decreased protein
level parallels the decrease in BamHI-Cp transcription. The
decrease in levels of LMP1 could either result from a diminution
in transactivation by EBNA1, or by a reduction in the levels of
EBNA2, as both proteins are known to transactivate the LMP1
promoter [11,12,13,72,73].
Finally, indirect immunofluorescence was used to determine
whether oxidative stress altered the sub-cellular localization of
EBNA1, as has been observed for other transactivators. This
analysis is shown in Figure 8C, and indicates that although small
changes in the nuclear localization of EBNA1 are observed even
by 48 hours of exposure to paraquat, the majority of EBNA1
remains nuclear. During microscopy, mitotic figures were
observed for approximately 5% of control cells, with punctate
EBNA1 staining (two such cells are shown in Figure 8C). Such
mitotic cells were rarely observed after even 48 hours of paraquat
treatment, consistent with the observation that treated cells
accumulate in G0/G1.
In summary, limited oxidative stress does not alter the levels or
nuclear localization of EBNA1, but decreases BamHI-Cp tran-
scription, and reduces EBNA2 and LMP1 levels. Concurrent with
these changes, treated cells accumulate in G0/G1.
Discussion
At the onset of these studies, it was known that deletion of UR1
abolished EBNA1’s ability to transactivate [10], and that UR1-
deleted EBV failed to immortalize naı ¨ve B-cells [2]. We have
dissected the mechanism by which UR1 functions for EBNA1 to
transactivate, and observed that transactivation is subject to
regulation by environmental conditions.
We have determined that the UR1 domain of EBNA1
coordinates zinc through two conserved, essential cysteines, and
upon doing so self-associates. Point mutation of these cysteines
eliminates the ability of EBNA1 to self-associate, coordinate zinc,
or activate transcription. In addition, chelation of intracellular zinc
severely impacts the ability of EBNA1 to activate transcription,
and blocks the ability of UR1 to support self-association. Together
these data provide the first evidence that a domain of EBNA1
necessary for transactivation coordinates zinc, and upon doing so,
allows EBNA1 to self-associate.
Because short motifs containing two cysteines residues have
been known to mediate heterotypic protein interactions, as
exemplified by the interaction between the lck kinase and CD4
or CD8 [74], we explored the possibility that through zinc
coordination UR1 permits EBNA1 to interact with another
protein such as a cellular transcription co-activator. Indeed, it has
been shown recently that the UR1 region of EBNA1 interacts with
the cellular Brd4 protein, and interpreted that this interaction
contributes to transactivation [43]. Our failure to find proteins
such as Brd4 could either reflect their rarity, or that co-activators
only associate with an array of EBNA1 bound to FR, a condition
not met by our two-hybrid screen. However, we note, that co-
activators were also not found in previous one-hybrid screens in
which FR-bound EBNA1 was used as bait [42,75]. In addition,
while deletion of UR1 severely reduces transactivation, an EBNA1
derivative with multiple copies of UR1 did not activate
transcription to higher levels than wild-type [76], as might be
expected if UR1 functions by recruiting a transcription coacti-
vator. Therefore, we propose that UR1 contributes structurally to
EBNA1’s ability to transactivate, when it is bound to FR. Such a
structural contribution likely explains our observation that while
the amino-terminal 450 a.a. of EBNA1 contains domains sufficient
for transactivation, it does not squelch EBNA1’s ability to
transactivate. The inefficiency with which FLAG-tagged
EBNA1(1-450)-E2DBD pulls down EBNA1 reinforces our belief
that for intact EBNA1, self-association through UR1 is facilitated
upon binding FR. An implication of the results obtained when
comparing transactivation by EBNA1 and EBNA1(CCRSS) is
that an intact UR1 domain is required for cooperative
transactivation. Thus, cooperative association with an array of
cognate binding sites by the DBD of EBNA1 does not solely
underlie EBNA1’s ability to activate transcription cooperatively.
The mechanisms for transactivation that we have considered
are grounded in the prior observation that EBNA1 contains a self-
interacting domain that maps to UR1 [16], and that several zinc-
coordinating domains are known to self-associate through
homotypic interactions. Examples of the latter include zinc-
binding domains within the Ikaros family of proteins [29], the E7
protein of HPV18 [19], and the Tat protein of HIV-1 [77].
Studies on many transactivators indicate that homotypic interac-
tions are often associated with structural changes in the template
that facilitate transactivation. These include architectural proteins
such as HMGA1a [28], cellular transcription factors such as p53,
Sp1, and Ikaros [30,32,78], and the E2 transactivator of HPV
[79,80].
Using these observations as precedent, and the knowledge that
for transactivation EBNA1 requires both UR1 and AT-hook
domains, we propose two models by which UR1 contributes to
transactivation. In the first model, it is speculated that UR1
mediates loop formation between EBNA1 bound to FR and as yet
Figure 8. Mild oxidative stress reduces transcription from the EBV BamHI-Cp in a lymphoblastoid cell-line. (A) Paraquat treatment
reduces the level of BamHI-Cp transcripts in treated NOLA-1 cells. Total RNA was extracted from control or cells exposed to 150 mM of paraquat for 48
or 72, reverse-transcribed with random hexamers. cDNA was used for real time PCR performed as described in the Methods section to evaluate
changes in Cp transcripts relative to the endogenous control GAPDH transcripts. The results are presented relative to the BamHI-Cp transcript level
observed in control cells, which was assigned a value of 1. Significant decreases in the level of BamHI-Cp transcripts were observed in cells with
paraquat for 48 and 72 hours, such that transcript level was reduced to approximately 60% after 48 hours of treatment, and approximately 40% after
72 hours of treatment. Cell-cycle analyses conducted with several treated samples indicates that paraquat treatment does not increase the sub-G1
population. However, treated cells were consistently observed to accumulate in G0/G1. Treatment caused a small increase in the number of necrotic
cells doubly-positive for annexin V and PI staining. Small increases were also seen for cells positive for only annexin V or only PI. (B) Paraquat
treatment decreases expression of EBNA2 and LMP1, as evaluated by immunoblot. 2610
5 control or cells treated with 150 mM paraquat (P150) for
72 hours were examined as described in Methods for expression of EBNA1, EBNA2 and LMP1. Band intensity was compared to that observed in
control cells, and is expressed as percent of control along with standard deviation from two experiments. Expression was normalized to the level of b-
actin protein detected in each sample. (C) Paraquat treatment does not alter the expression or localization of EBNA1. Control or treated cells were
transferred to slides by cytospin, prior to fixation and permeabilization. EBNA1 expression was evaluated using rabbit polyclonal Ab 2638 as
described in the methods, and detected using a TexasRed conjugated secondary anti-rabbit Ab. Cells were counterstained with Hoechst 33342. The
absence of paraquat exposure, or length of treatment with 150 mm paraquat is indicated above each panel. Detection of EBNA1-specific signal,
Hoechst signal and the merge is also indicated. The scale bar represents a distance of 10 mM.
doi:10.1371/journal.ppat.1000469.g008
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the association of EBNA1’s AT-hooks with AT-rich sequences
present at EBV promoters such as BamHI-Cp. In the second
model, which we believe is more consistent with our data, we
propose that UR1 facilitates interactions between EBNA1 dimers
bound to adjacent sites in FR to create a structured array of
EBNA1 at FR. Further, that the structure presented by such an
array facilitates the interaction of EBNA1’s AT-hooks with
promoter proximal AT-rich sequences, and the possible recruit-
ment of co-activators.
The mechanism by which UR1 dimerizes suggests that
transactivation can be regulated by the availability of zinc, and
by modulating the ability of the two conserved cysteines in UR1 to
participate in zinc coordination. Zinc levels are known to differ in
various body compartments, and the function of immune cells is
dependent on zinc [81,82]. Therefore, it is possible that the site a
latently-infected cell resides in affects the function of EBNA1
within that cell. Cellular zinc homeostasis is known to be regulated
finely [83], and has recently been shown to be relevant to the
pathogenesis of oncogenic papillomaviral infections, through the
action of the viral E6 and E7 proteins on cellular zinc-binding
proteins such as metallothioneins [84], and modulation of cellular
zinc transporters by the viral E5 protein [85]. Cellular zinc
availability directly affects the activity of the eukaryotic transacti-
vators such as MTF-1 in human cells [86,87], ZafA in Aspergillus
[88], and Zap1 in Saccharomyces [89].
The oxidation status of cysteines affects the activities of many
proteins that participate in gene expression including transcription
factors and the SMN splicing complex [53,55]. Such an effect is
pronounced for zinc-binding proteins whose structure and
function are altered by cysteine oxidation. Indeed, it is estimated
that estrogen receptor isolated from approximately one-third of
untreated ER-positive breast tumors is unable to bind its cognate
binding site [52], a defect that can be reversed by treating cell
extracts with reducing agents such as dithiothreitol [90]. For some
zinc-finger proteins such as Egr-1, over-expression of the cellular
redox mediator, Ref-1/APE1, and hypoxic conditions are shown
to increase activity both by increasing the synthesis of Egr-1, and
facilitating its nuclear translocation [91]. For the glucocorticoid
receptor, redox modulates nuclear translocation in addition to
DNA binding [92].
It is intriguing that the ability of EBNA1 to transactivate is
modulated by intracellular redox, and that the activity of EBNA1
differs under normoxic and hypoxic conditions. B-cells latently
infected by EBV exist as proliferating blasts in lymph nodes
expressing all the latency-associated genes necessary for cell
proliferation (latency III), and as a subset of quiescent memory B-
cells in the periphery where the only viral protein expressed is
EBNA1, and that too only when cells divide (latency 0/I) [62,63].
This striking difference in phenotype correlates with epigenetic
changes associated with viral promoters active during latency III
and shutdown during latency I. There are prominent physiological
differences between these two niches that latently-infected cells
reside in. Sites like the spleen, thymus and lymph nodes are
hypoxic with an effective oxygen level of between 2% and 5%. In
contrast, the periphery is relatively oxygen-rich, with an effective
oxygen level of approximately 10%. Studies conducted over the
last 40 years have indicated that oxygen levels affect the behavior
of B-cells; Mishell and Dutton [93] first showed that the
proliferation and antibody production properties of murine splenic
B-cells was augmented considerably under hypoxic conditions.
There have been studies since then indicating that cytokine
production properties of T-cells and B-cell differ considerably
when the cells are grown under hypoxic conditions that mimic
oxygen levels in vivo, or under normoxic conditions that typically
prevail when cells are grown in culture [59,94].
Exposure of a proliferating EBV-immortalized LCL to mild
oxidative stress decreases transcription from the viral BamHI-C
promoter, consistent with observation made with transcription
reporter plasmids in transformed cell-lines. This decrease in
transcription manifests itself as decreased levels of the viral EBNA2
and LMP1 proteins, which are essential for the continued
proliferation of EBV-immortalized cells [95,96]. Treatment was
not observed to affect LCL survival, although treated cells did
accumulate in G0/G1. As such, there are parallels between these
results, and those obtained with recombinant EBVs expressing
conditional derivatives of EBNA2 and LMP1 (ibid). Conditional
inactivation of EBNA2 after immortalization results in a rapid
depletion of LMP1. Such cells exit the cell-cycle, and undergo
necrosis [95]. It is likely that our treated cells do not undergo
necrosis because EBNA2 and LMP1 are only partially depleted.
Conditional inactivation of LMP1 causes newly-infected cells to
become cell-cycle arrested, but survive quiescently [96]. It is
known that the expression level of LMP1, as well as its sub-cellular
localization can dramatically affect cellular physiology
[97,98,99,100]. Thus although we observe only a 50% decrease
in the level of LMP1, this decrease may be sufficient to down-
modulate mitogenic signals required for cell proliferation.
While it has been long known that hypoxic conditions alter the
propagation and pathogenicity of bacterial, viral and eukaryotic
pathogens, the molecular details elucidating these effects have
emerged more recently. Redox controls the activity of the OxyR
family of prokaryotic transactivators, such that changing culture
conditions from anaerobic to aerobic induces the expression of
OxyR-induced genes [101]. The Tat protein of HIV-1 induces
apoptosis of naı ¨ve T-cells under normoxic conditions; yet, at
physiological oxygen levels (hypoxic conditions), Tat stimulates T-
cell proliferation, and primes them for infection by HIV-1 [102].
The ability of the papillomaviral E2 protein [103], and EBV’s
lytic transactivator BZLF1/Zta [104] to support replication is
regulated by redox. Our results raise the intriguing possibility that
in the severely hypoxic conditions prevalent in lymph nodes
EBNA1 transactivates the expression of viral genes required for
cell proliferation, but when such cells escape to the periphery,
higher oxygen levels gradually diminish the ability of EBNA1 to
transactivate while leaving intact its ability to maintain viral
genomes. This model is consistent with the observation that
EBNA1 with UR1 deleted continues to support EBV genome
replication and partitioning, and is not inconsistent with the
ability of EBV to efficiently immortalize B-cells grown in vitro
under normoxic conditions. It is known that exposure of primary
cells under hypoxic conditions to normoxia induces the
expression of redox genes, particularly thioredoxin, and consistent
with this, established EBV-positive lymphoma lines grown in vitro
express considerably higher levels of thioredoxin than primary B-
cells [105].
In summary, our studies provide mechanistic insights that
underpin the ability of EBNA1 to self-associate and to activate
transcription. Transactivation by EBNA1 relies on its ability to
interact homotypically by coordinating zinc through two con-
served cysteines. EBNA1’s ability to transactivate is subject to
regulation by the availability of zinc, and oxygen levels in the
environment, implying a mechanism to modulate EBNA1’s ability
to transactivate without affecting its ability to stably maintain EBV
episomes. The regulatory model proposed here for EBNA1 is
likely applicable to proteins of other viral, prokaryotic, and
eukaryotic pathogens that traffic between environmentally distinct
niches within the body.
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Effector and reporter plasmids
Plasmids expressing wild-type EBNA1, the EBNA1 DBD and
HMGA1a-DBD have been described previously [6,26,106].
Similar plasmids were constructed to express EBNA1D(71-88),
EBNA1(CCRSS), and UR1-DBD. The chimeric protein 3xF-
EBNA1(1-450)-E2DBD was constructed by fusing a.a. 1–450 of
EBNA1 fused to a.a. 239–410 of BPV-1 E2, with a 3xFLAG
epitope tag at the amino-terminus of EBNA1. The chimeric
protein DBD-VP16 was constructed by fusing the EBNA1 DBD to
a.a.413–490 of HSV-1 VP16. For bimolecular fluorescence
complementation, a.a. 61–90 of EBNA1 was fused independently
to a.a. 155–238, and 2–154 of EYFP. FR-TKp-luciferase [3]
reporter plasmid and oriP-BamHI-Cp-luciferase reporter plasmid
[26] were described previously. The 2xMME-TKp-luciferase
reporter, was constructed by replacing FR in FR-TKp-luciferase
with two copies of the BPV-1 MME [107]. The Ref-1/APE1
expression plasmid was a gift from Dr. Tadahide Izumi.
Derivatives of the FR-TKp-luciferase reporter plasmids with
one, three, five, seven, ten, and 20 binding sites have been
described previously [3].
Cell culture
Experiments were performed in C33a (HPV-negative) cervical
cancer cells, BJAB (EBV-negative) Burkitt’s lymphoma cells, and
293 human embryonic kidney epithelial cells, propagated and
transfected as described previously [3,5,6]. NOLA-1 is a
lymphoblastoid cell-line established from the peripheral B-cells
of an HIV-1 negative donor by infection with B95-8 EBV, using
established protocols [108]. Cells used for these experiments have
been passaged fewer than fifteen times after an immortalized clone
was obtained.
Immunoblotting
Proteins were immunoblotted as described earlier [5,6]. Rabbit
polyclonal antibody K67.3 was used to detect EBNA1, and the M2
mouse monoclonal anti-FLAG antibody (Sigma, St. Louis, MO)
was used to detect FLAG-tagged proteins. Goat polyclonal
antibody 2824 was used to detect EBNA2, and rabbit polyclonal
antibodies 2825/2826 were used to detect LMP1. Polyclonal
antibodies against EBNA1, EBNA2 and LMP1 were obtained
from Pacific Immunology using three antigenic peptides from each
protein. Mouse monoclonal antibody (8226) against b-actin was
purchased from Abcam (Cambridge, MA).
Luciferase reporter assays
Reporter assays were performed as described earlier [3] using
500 ng of the reporter plasmid and 10 mg of the effector plasmid.
Flow cytometry was used to normalize raw luciferase values to
correct for the percent of live-transfected cells (PI-negative, GFP-
positive) in each transfection. In experiments examining cooper-
ative transactivation, 100 ng of each reporter plasmid was co-
transfected with 1 mg of the effector plasmid and 500 ng of a GFP
expression plasmid. Raw luciferase values were corrected for the
percent of live-transfected cells. Cooperativity plots were gener-
ated by non-linear regression analysis fit to a sigmoidal dose-
response curve using Prism (GraphPad Software, La Jolla, CA).
Metal-ion chelation and supplementation
N, N, N9,N 9-Tetrakis- (2-pyridylmethyl)-Ethylenediamine
(TPEN) (Sigma, St Louis, MO) was used to chelate zinc. After
transfection, cells were incubated with TPEN for 15 hours,
following which they were analyzed to determine the percent of
live-transfected cells, the cell-cycle profile, and luciferase activity.
In supplementation experiments, the indicated metal salt was
added to media already containing TPEN. Metals were added as
solutions of the followings salts, zinc acetate, cadmium acetate,
ferrous acetate, calcium chloride, manganese chloride, and
magnesium sulfate. All salts were purchased at the highest purity
available from Fisher Scientific, Pittsburgh, PA.
Zinc
65 blotting
Radioactive zinc blotting was done as described previously
[17,18,19]. Briefly, synthetic peptides were obtained at .99%
purity and resuspended in 50 mM Tris pH 7.4 at 10 mg/ml
(Peptide 2.0, Chantilly, VA). The WT peptides corresponded to
a.a 58–89 of wild type EBNA1 (WT) or the cysteine to serine
mutant (M) described above. WT and M peptides were blotted on
a PVDF membrane. Membranes were incubated with approxi-
mately 50 mCi of
65ZnCl2 (specific activity .0442 mCi/mg, Oak
Ridge National Laboratory, Oak Ridge, TN) for 30 minutes at
room temperature, washed and analyzed by phosphor-imaging.
Membranes prepared in parallel, were stained with Amido-Black.
Co-immunoprecipitation
293 cells were co-transfected with plasmids expressing
EBNA1(1-450)-E2DBD, and EBNA1 or EBNA1(CCRSS). Co-
immunoprecipitation was performed as described [5] using the M2
mouse monoclonal antibody conjugated to sepharose beads.
Immunoprecipitates were detected using M2 anti-FLAG antibody
(Sigma, St. Louis, MO), or K67.3 anti-EBNA1 antibody.
Bimolecular fluorescence complementation (BiFC)
293 cells were co-transfected with plasmids expressing EYFP(2-
154) and EYFP(155-38), or the corresponding UR1 fusions. Fixed
cells were examined by fluorescence microscopy 48 hours post-
transfection. In some experiments, the zinc chelator 1,10-
phenanthroline (Fisher Scientific, Pittsburgh, PA) was added
24 hours prior to microscopy. To analyze the effect of redox,
menadione (MP Biomedicals, Solon, OH) in various concentra-
tions was added to the culture medium six hours post-transfection.
Size exclusion chromatography
Size exclusion chromatography was performed using a Biosep-
SEC-S2000 (600630 mm) (Phenomenex, Torrance, CA) column on
a Bio-Rad BioLogic Duo Flow system, to examine the ability of WT
and M peptides to form dimers or higher order multimers. The
column was equilibrated with a buffer consisting of 50 mM NaCl and
50 mM Tris (pH 7.5), and run in the same buffer at 0.8 ml/min
(approximately 730 psi) for 50 minutes after sample injection.
Molecular weights were calculated after the column was calibrated
with Bio-Rad gel filtration standards ranging in size from 1.35 to 670
kD. Elution from the column was monitored by absorption at 280,
225, 215 and 205 nm using a QuadTech inline detector. For
calculation, the log of the molecular weights of standards was plotted
against retention time. The method was found to be as accurate as
using the ratio of the elution volume to the void volume, and was
validated by calculating the molecular weight of purified ubiquitin
and cytochrome C based on their retention times. When the effect of
zinc on multimerization was tested, it was added to the peptide at a
final concentration of 1 mM.
Redox experiments
C33a cells were transfected as described [3] with plasmids as
depicted in Figure 6. Six hours post-transfection, cells were split
and treated with menadione or paraquat for 18 hours following
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activity.
Hypoxia experiments
C33a cells were transfected as described [3]. Six hours post-
transfection, cells were split, and grown under normoxic
conditions, or hypoxic conditions. For hypoxic conditions, cells
were grown in a sealed modular incubation chamber (Billups-
Rothenberg, Inc, Del Mar, CA) placed at 37
oC. Prior to sealing,
the chamber was flushed with a mixture of 4%O2, 5%CO2 and
91%N2 gas (AirGas, Theodore, AL) for five minutes. Culture
media was replaced with fresh media every 24 hours that was pre-
equilibrated to normoxic or hypoxic conditions, at which time the
chamber was re-flushed and re-sealed. No significant differences in
doubling rate were observed between normoxic and hypoxic
conditions. Southern blots were performed as described [3] using
probes specific for oriP-BamHI-Cp-luciferase.
Flow cytometry analyses
Apoptosis and necrosis was evaluated by flow cytometry using
the Annexin V-FITC apoptosis detection kit (EMD Biosciences,
Gibbstown, NJ) as per the manufacturers protocol, and examined
using a FACSCalibur flow cytometer. Cell-cycle analysis was
performed after PI-staining of fixed cells using a FACSCalibur.
Real time PCR
Total cellular RNA was extracted using TRI Reagent (Ambion,
Austin, TX), following which cDNA was prepared using TaqMan
reverse transcriptase reagents (Applied Biosystems, Foster City,
CA). Real time PCR was performed using the ABsolute blue
QPCR Rox mix (Thermo Fisher, Germantown, PA) on an ABI
7300 real time PCR system (Applied Biosystems, Foster City, CA).
The primer and probe sequences used for the detection of BamHI-
Cp transcripts and the endogenous control GAPDH mRNA have
been described [109]. Relative quantitation was performed by the
dCt method, and is expressed relative to the level of normalized
BamHI-Cp transcripts detected in control cells.
Immunofluorescence microscopy
Control or treated NOLA-1 cells were examined by immuno-
fluorescence using microscopy conditions described previously
[76]. Rabbit polyclonal antibodies 2638 or K67.3 was used to
detect EBNA1 with a TexasRed conjugated anti-rabbit secondary
antibody (Jackson ImmunoResearch, West Grove, PA).
Statistical analysis
All the statistical analysis where indicated was performed using
MSTAT version 5 (N, Drinkwater, McArdle Laboratory for
Cancer Research, University of Wisconsin Medical School). The
Wilcoxon rank sum test was used for pair-wise comparisons.
Supporting Information
Figure S1 Expression of the EBNA1 derivatives analyzed in
Figure 1B. Extracts from 5610
5 transfected C33a cells were
separated by SDS-PAGE electrophoresis, and examined by
immunoblot as described in the Materials and Methods section.
Rabbit polyclonal antisera (K67.3), raised against the DBD, was
used as the primary antibody. The arrowheads indicate the
migration of pre-stained markers of known molecular weights.
Found at: doi:10.1371/journal.ppat.1000469.s001 (2.32 MB TIF)
Figure S2 Expression of the EBNA1 and EBNA1(CCRSS) in
transfected C33a cells. Extracts from 5610
5 cells were separated
by SDS-PAGE electrophoresis, and examined by immunoblot as
described in the Materials and Methods section, using K67.3 as
the primary antibody. The arrowheads indicate the migration of
pre-stained markers of known molecular weights.
Found at: doi:10.1371/journal.ppat.1000469.s002 (0.62 MB TIF)
Figure S3 The addition of zinc acetate reverses inhibition of
transactivation caused by TPEN. C33a cells were co-transfected
with the FR-TKp-Luciferase reporter plasmid, an EBNA1
expression plasmid, and a CMV-EGFP expression plasmid.
Transfected cells were treated with 5 mM TPEN at the time of
transfection. 15 hours post-TPEN addition, the indicated amounts
of Zn(CH3COO)2 was added to the cells for an additional
15 hours. Cells were harvested and analyzed by flow cytometry to
determine the level of lice-transfected cells, followed by determi-
nation of luciferase activity. The relative activation is shown in the
grey bars, and is expressed as a percent of the luciferase activity
observed in the untreated sample. The asterisks indicate significant
increases (p,0.05 by Wilcoxon rank-sum test) in luciferase level
upon addition of Zn(CH3COO)2 relative to addition of TPEN
alone. The open bars indicate the percent of live EGFP-positive
cells at each concentration of TPEN and Zn(CH3COO)2.
Found at: doi:10.1371/journal.ppat.1000469.s003 (0.31 MB TIF)
Figure S4 EBNA1(1-450)-E2DBD activates transcription from
the 2xMME-TKp-Luciferase reporter. C33a cells were co-
transfected with the 2xMME-TKp-Luciferase reporter plasmid,
empty vector pcDNA3 or the EBNA1-E2DBD expression
plasmid. Cells were harvested at 48 hours post-transfection,
normalized by flow cytometry for the number of live-transfected
cells, and analyzed for luciferase activity, which is expressed as fold
activation relative to pcDNA3.
Found at: doi:10.1371/journal.ppat.1000469.s004 (0.22 MB TIF)
Figure S5 TPEN inhibits activation of 2xMME-TKp-luciferase
by 3xF-EBNA1(1-450)-E2DBD. C33a cells were co-transfected
with the 2xMME-TKp-Luciferase reporter plasmid, and the 3xF-
EBNA1(1-450)-E2DBD expression plasmid. Transfected cells were
treated with 5 mM TPEN for 15 hours and then analyzed, or with
5 mM TPEN for 15 hours followed by the addition of 5 mM
Zn(CH3COO)2 for 15 additional hours prior to analysis. At
harvest cells were analyzed by flow cytometry to determine the
fraction of live-transfected cells, followed by assays for luciferase
activity. The grey bars in the graph represent luciferase activity,
which is expressed as a function of the luciferase activity observed
in the absence of TPEN treatment 15 hours post-transfection.
Found at: doi:10.1371/journal.ppat.1000469.s005 (0.26 MB TIF)
Figure S6 Paraquat reduces the ability of EBNA1 to transacti-
vate FR-TKp-Luciferase. C33a cells were co-transfected the FR-
TKp-Luciferase reporter plasmid, and an EBNA1-expression
plasmid. Cells were treated with the indicated levels of paraquat
six hours post-transfection, and harvested 18 hours later. For cell-
cycle analysis, an aliquot of cells was fixed and then PI-stained.
The rest of the cells were processed to determine luciferase
activity, which is expressed as a percent of the luciferase activity
observed in the absence of paraquat treatment, The cell-cycle
profiles of paraquat-treated and control cells were obtained for one
experiment, and are shown below the graph.
Found at: doi:10.1371/journal.ppat.1000469.s006 (0.33 MB TIF)
Figure S7 Menadione does not decrease transactivation by
DBD-VP16. C33a cells were co-transfected with the FR-TKp-
Luciferase reporter plasmid and 2 mg of the DBD-VP16
expression plasmid. Cells were split six hours post-transfection,
at which time half were treated with 1.4 mM menadione for
18 hours. Luciferase levels were determined 24 hours post-
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observed in the untreated cells.
Found at: doi:10.1371/journal.ppat.1000469.s007 (0.21 MB TIF)
Figure S8 Over-expression of Ref-1/APE1 ameliorates the
effect of paraquat on EBNA1 mediated transactivation. C33a
cells were transfected with an EBNA1 expression plasmid, and
either 2 mg of a Ref-1/APE1 expression plasmid or empty vector
control plasmid in addition to the FR-TKp-luciferase reporter
plasmid. Six hours post-transfection, the cells were split and half
the cells were treated with 150 mM of paraquat. Luciferase levels
were evaluated 24 hours post-transfection.
Found at: doi:10.1371/journal.ppat.1000469.s008 (0.29 MB TIF)
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